Friday, July 4, 2025 7/4/2025

Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas

Award Number: R37CA214955
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/11/2017
PERIOD OF PERFORMANCE END DATE: 02/28/2025

Group Awards By:

View Award Description

Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas - Project Summary: Title: Synthesizing Image-derived Heterogeneity with Genomic Measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas WHO Grade II low grade gliomas (LGGs) are a type of brain tumor with an average incidence of 1/100,000 person-years within the population. Approximately 4000 people are diagnosed with this disease each year. It has been observed that even after the first line of therapy (surgery, chemo-radiation), this disease inevitably recurs. Further, it eventually transforms to a higher grade (WHO Grade III/IV) over time, a process referred to as malignant transformation (MT). Even though MT is almost inevitable, the time-to-MT can be quite variable. In aggressive cases, the LGG can undergo MT quite early in disease course, while in other (less aggressive) cases, the duration to MT is much longer. This variability in time-to-MT can spell very disparate prognoses for the patient. Such uncertainty in the disease evolution of LGGs also creates significant challenges for treatment man- agement. Apart from creating uncertainty for the oncologist as how to appropriately manage the disease, this also creates an anxiety-ridden scenario for the patients and their caregivers who try to understand their individual condition. A rational strategy to understand and characterize the aggressiveness of LGGs can provide valuable insight into the appropriate approach of treatment and surveillance for these patients. In this proposal, we will address three specific aims that build a comprehensive, integrative statistical model, which incorporates novel, complex imaging predictors, in addition to standard clinical and genomic characteris- tics, for informing time-to-malignant transformation of LGGs. This tool can provide an assessment of anticipated disease course that will help the patient and physician make suitable treatment decisions as well as to design appropriate monitoring methods to track the progression and status of the tumor. Such a tool can also help ameliorate some of the uncertainty and anxiety for the patients and their caregivers who will be better equipped to understand their individual disease, in addition to enabling a more effective collaboration between patient and physician to determine the most appropriate treatment approach. In particular, we will develop novel tumor het- erogeneity objects, which efficiently capture inter- and intra-tumor variation in morphology and intensity-distribu- tion characteristics. These objects are functional in nature and lie on nonlinear spaces. This introduces a signif- icant challenge in statistical analysis such as defining association measures between the tumor heterogeneity objects and genomic covariates, or incorporating these objects as predictors in an integrative statistical model. To address these goals, we will use data on WHO Grade II LGG patients treated at the University of Texas MD Anderson Cancer Center to identify imaging, genomic and clinical characteristics of malignant transformation. This dataset is unique because, aside from imaging (radiographic) and genomic information, there is carefully curated clinical data about the disease course of every patient (such as overall survival and time-to-malignant transformation).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $565,085 )
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	002	8	2/21/2024	NON-COMPETING CONTINUATION	$535,345
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	003	8	4/17/2024	NON-COMPETING CONTINUATION	$29,740
2024	2023	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	7	2/14/2024	EXTENSION WITH OR WITHOUT FUNDS	$458,833
2024	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	6	2/14/2024	NON-COMPETING CONTINUATION	-$458,833
														Subtotal = $565,085

Issue Date FY: 2023 ( Subtotal = $604,346 )
2023	2023	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON STREET	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	7	3/17/2023	EXTENSION WITH OR WITHOUT FUNDS	$604,346
														Subtotal = $604,346

Issue Date FY: 2022 ( Subtotal = $553,851 )
2022	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	6	5/10/2022	NON-COMPETING CONTINUATION	$55,386
2022	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	6	1/6/2022	NON-COMPETING CONTINUATION	$498,465
														Subtotal = $553,851

Issue Date FY: 2021 ( Subtotal = $560,491 )
2021	2021	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	002	5	3/23/2021	NON-COMPETING CONTINUATION	$0
2021	2021	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	5	2/2/2021	NON-COMPETING CONTINUATION	$28,024
2021	2021	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	5	11/25/2020	NON-COMPETING CONTINUATION	$532,467
														Subtotal = $560,491

Issue Date FY: 2020 ( Subtotal = $517,367 )
2020	2020	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	4	1/14/2020	NON-COMPETING CONTINUATION	$51,737
2020	2020	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	4	11/26/2019	NON-COMPETING CONTINUATION	$465,630
														Subtotal = $517,367

Issue Date FY: 2019 ( Subtotal = $496,651 )
2019	2019	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	3	1/16/2019	NON-COMPETING CONTINUATION	$496,651
2019	2018	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Detection and Diagnosis Research	000	1	11/7/2018	NEW	$0
2019	2018	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	002	2	1/16/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $496,651

Issue Date FY: 2018 ( Subtotal = $589,804 )
2018	2018	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Detection and Diagnosis Research	000	1	12/11/2017	NEW	$589,523
2018	2018	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Detection and Diagnosis Research	001	1	9/20/2018	NEW	-$553,831
2018	2018	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	002	2	9/20/2018	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$554,112
														Subtotal = $589,804

Grand Total All Awards = $3,887,595

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas

Award Number: R37CA214955

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/11/2017

PERIOD OF PERFORMANCE END DATE: 02/28/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer